Wall Street and stocks rally, halving losses from a dismal week as inflation data boosts stock market sentiment.

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

The first tip came into West Tennessee law enforcement about two months ago: A resident in the area was selling cheap versions of Ozempic and other weight loss drugs. According to officials with ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

By Dani Blum The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the ...

(AP/Brandon Dill) Stephen Curry's unprecedented scoreless performance highlights Warriors' worst loss of the season against Memphis. Golden State experiences third 50+ point loss in five years, ...

Weight loss refers to a decrease in your overall body weight from muscle, water, and fat loss. Fat loss refers to weight loss from fat only, and it’s a more specific and healthy goal than ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The decision ...

Reuters has earlier reported that two copies of Novo's weight-loss and diabetes drugs, Orsema and Fitaro, had been approved ...

"We plan to optimise dose titration to further explore CagriSema's additional weight loss potential with a new trial planned to start in the first half of 2025," a company spokesperson said in an ...

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking. By Dani Blum Dani Blum met with over a dozen doctors and patients in ...

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat ...